GB-0998 clinical trials
Also written GB-0998.
How each study uses GB-0998 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2013 | 1 |
| 2014 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Japan Blood Products Organization (4)
Studies
Open first, then newest update. How each study uses GB-0998 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of the Efficacy and Safety of GB-0998 in Patients With Unexplained Recurrent MiscarriageCompletedPhase 3Japan Blood Products OrganizationNCT02184741Written as GB-0998
- The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.CompletedPhase 2/3Japan Blood Products OrganizationNCT02032095Written as GB-0998
- Efficacy and Safety Study of GB-0998 for Guillain-Barré SyndromeCompletedPhase 3Japan Blood Products OrganizationNCT02342184Written as GB-0998
- Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM)CompletedPhase 3Japan Blood Products OrganizationNCT00335985Written as GB-0998